Indeed, the OS rate was lower in patients with dMLH1 stage III CRC harboring also the RIPMSI mutation (p = 0.0006) (Figure 6D), whereas it was comparable in patients with MLH1-proficient tumors with/without the RIPMSI mutation (Figure 6E). This evidence concerns the gene MLH1 and colorectal carcinoma.